BNR Stock Overview
Primarily develops and sells cancer therapy selection tests in the People's Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Burning Rock Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.15 |
| 52 Week High | US$20.55 |
| 52 Week Low | US$7.15 |
| Beta | 0.18 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNR | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -1.5% |
| 1Y | n/a | -25.8% | 5.8% |
Return vs Industry: Insufficient data to determine how BNR performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BNR performed against the UK Market.
Price Volatility
| BNR volatility | |
|---|---|
| BNR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BNR has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BNR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 786 | Yusheng Han | www.brbiotech.com |
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Burning Rock Biotech Limited Fundamentals Summary
| BNR fundamental statistics | |
|---|---|
| Market cap | US$63.55m |
| Earnings (TTM) | -US$81.12m |
| Revenue (TTM) | US$71.57m |
0.9x
P/S Ratio-0.8x
P/E RatioIs BNR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNR income statement (TTM) | |
|---|---|
| Revenue | CN¥520.54m |
| Cost of Revenue | CN¥170.39m |
| Gross Profit | CN¥350.15m |
| Other Expenses | CN¥940.13m |
| Earnings | -CN¥589.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -57.51 |
| Gross Margin | 67.27% |
| Net Profit Margin | -113.34% |
| Debt/Equity Ratio | 0% |
How did BNR perform over the long term?
See historical performance and comparison